Experimental CAR-T therapy takes aim at Tough-to-Treat myasthenia gravis
NCT ID NCT07058298
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early study tests a new treatment called GC012F, made from a patient's own immune cells (CAR-T cells), for people with refractory generalized myasthenia gravis that hasn't responded to standard therapies. Six participants will receive a single infusion of these modified cells after a short chemotherapy prep. The main goal is to check safety and tolerability, while also looking for signs of improvement.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GC012F injection (CAR-T cells)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-control myasthenia gravis.
What could go wrong
This is a very early, small trial with only 6 people, so results may not apply widely. CAR-T therapy can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS (GMG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital of Tongji Medical Colledge, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Contact